Geode Capital Management, LLC Chinook Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $2.09 Million - $4.32 Million	111,866 Added 11.79%	1,060,417 $40.7 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $739,017 - $919,910	34,325 Added 3.75%	948,551 $22 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $739,033 - $1.08 Million	39,669 Added 4.54%	914,226 $24 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $778,897 - $1.04 Million	44,483 Added 5.36%	874,557 $17.2 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $667,370 - $996,550	53,008 Added 6.82%	830,074 $14.5 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $521,776 - $724,496	43,409 Added 5.92%	777,066 $12.7 Million
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $1.22 Million - $1.92 Million	113,888 Added 18.38%	733,657 $12 Million
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $12,224 - $15,796	1,063 Added 0.17%	619,769 $7.91 Million
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $2.35 Million - $3.28 Million	172,669 Added 38.71%	618,706 $8.74 Million
Q1 2021 May 12, 2021	BUY	$14.17 - $19.11 $507,526 - $684,462	35,817 Added 8.73%	446,037 $6.93 Million
Q4 2020 Feb 12, 2021	BUY	$11.9 - $20.91 $4.88 Million - $8.58 Million	410,220 New	410,220 $6.51 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.